NASDAQ · TERN
Terns Pharmaceuticals, Inc.
$52.95-$0.02 (-0.03%)
Terns Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.45% below the high.
Loading market information…
NASDAQ · TRML · USD
Stock price, dividends, earnings
Quote as of Oct 28, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tourmaline Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 19, 2024 |
| -$0.81-8.0% vs estimate |
| $2.28M |
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$52.95-$0.02 (-0.03%)
Terns Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.45% below the high.
$81.97-$0.74 (-0.89%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.47% below the high.
$18.55-$0.92 (-4.74%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.8% below the high.
$28.70+$0.02 (+0.07%)
Amylyx Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.24% below the high.
$44.89-$0.19 (-0.42%)
Enliven Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.97% below the high.
$6.67+$0.03 (+0.39%)
Precigen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.77% below the high.
$13.73-$0.42 (-2.95%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.34% below the high.
$6.88-$0.44 (-5.95%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 44.6% below the high.
